Company Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.
Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China.
The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020.
Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Robert E. Hoffman B.B.A., CPA |
Contact Details
Address: 9920 Pacific Heights Blvd, Suite 150 San Diego, California 92121 United States | |
| Phone | (858) 350-4364 |
| Website | kintara.com |
Stock Details
| Ticker Symbol | KTRA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| CUSIP Number | 49720K101 |
| ISIN Number | US49720K2006 |
| Employer ID | 99-0360497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert E. Hoffman B.B.A., CPA | President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board |
| Jeffrey A. Bacha B.Sc., M.B.A. | Founder |
| Greg A. Johnson | Acting Head of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | 425 | Filing |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 13, 2024 | RW | Filing |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Feb 12, 2024 | 8-K | Current Report |
| Dec 18, 2023 | 8-K | Current Report |